Juliana Salazar

16PUBLICATIONS
45CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursTumour immunologyRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 26, 2026
Exploring Dystrophin Expression and Mutations in the DMD and Dystrophin-Glycoprotein Complex Genes as Prognostic Factors in Leiomyosarcomas.

|Dec 31, 2025
VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol.

Juliana Salazar, María J Arranz, Javier Martin-Broto

|May 14, 2025
CD274 (PD-L1) Polymorphisms as Predictors of Efficacy in First-Line Platinum-Based Chemotherapy for Extensive-Stage Small Cell Lung Cancer.

Andrés Barba, Laura López-Vilaró, Malena Ferre

|Jan 08, 2025
Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol.

Juliana Salazar, María J Arranz, Javier Martin-Broto

|Sep 28, 2024
ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer.

Andrés Barba, Laura López-Vilaró, Malena Ferre

|Jun 21, 2024
Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn's disease patients.

Juliana Salazar, Pau Riera, Jordi Gordillo

Pageof 3

Frequent Collaborators

7 joint publications

María Jesús Arranz

4 joint publications

Pau Riera

3 joint publications

Silvia Bagué

3 joint publications

Ruth Orellana